Arch Therapeutics, Inc.
ARTHQ
$0.0001
$0.000.00%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 291.03% | 322.65% | 567.05% | 382.80% | 141.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 291.03% | 322.65% | 567.05% | 382.80% | 141.40% |
| Cost of Revenue | 63.21% | 62.62% | 61.11% | 51.95% | -18.67% |
| Gross Profit | 438.73% | 289.57% | 188.64% | 93.04% | 66.67% |
| SG&A Expenses | -9.50% | -8.93% | 5.05% | -3.28% | -5.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.25% | -6.47% | -2.06% | -10.56% | -13.54% |
| Operating Income | 8.43% | 8.44% | 3.86% | 11.64% | 13.95% |
| Income Before Tax | -91.18% | -49.54% | -42.32% | -32.36% | -24.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -91.18% | -49.54% | -42.32% | -32.36% | -24.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -91.18% | -49.54% | -42.32% | -32.36% | -24.49% |
| EBIT | 8.43% | 8.44% | 3.86% | 11.64% | 13.95% |
| EBITDA | 8.44% | 8.43% | 3.84% | 11.62% | 13.93% |
| EPS Basic | 48.54% | 42.70% | 33.51% | 11.61% | -17.17% |
| Normalized Basic EPS | 51.77% | 42.70% | 33.51% | 11.61% | -17.17% |
| EPS Diluted | 48.54% | 42.70% | 33.51% | 11.61% | -17.17% |
| Normalized Diluted EPS | 51.77% | 42.70% | 33.51% | 11.61% | -17.17% |
| Average Basic Shares Outstanding | 339.60% | 284.06% | 223.85% | 156.20% | 6.33% |
| Average Diluted Shares Outstanding | 339.60% | 284.06% | 223.85% | 156.20% | 6.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |